Lilly Halts Trials Of PPAR Alpha Agonist After Preclinical Safety Signal
This article was originally published in The Pink Sheet Daily
Executive Summary
Phase II clinical trials of the atherosclerosis treatment candidate LY674 were halted after a primate study showed fatty liver deposits.
You may also be interested in...
Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback
Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.
Roche Drops Aleglitazar In Another Cardiology/Metabolics Setback
Development of dual PPAR agonist aleglitazar terminated due to fractures, renal impairment and heart failure reported in the AleCardio study, leaving another hole in Roche’s cardiovascular/metabolic pipeline.
Bristol Joins The Ranks: Firm Bags Pargluva Development
Merck, AstraZeneca and Roche have already stepped out of the dual PPAR development arena.